High-purity therapeutic building blocks, custom peptide APIs, and pharmaceutical raw materials engineered under rigorous cGMP protocols.
The global demand for specialized therapeutics targeting respiratory diseases—ranging from Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), asthma, pulmonary hypertension, to idiopathic pulmonary fibrosis—has driven unprecedented structural evolution across global biopharmaceutical supply chains. In this landscape, qualified OEM Respiratory System Exporters & Companies play a vital, foundational role. Modern clinical therapeutics require not only ultra-high-purity Active Pharmaceutical Ingredients (APIs) and advanced peptide building blocks, but also flexible, cGMP-compliant scale-up infrastructure capable of transitioning molecules seamlessly from benchtop laboratory discovery to global commercial delivery.
As a premier contract development and manufacturing enterprise, Gentolex Group stands at the forefront of this industrial transformation. By leveraging a massive manufacturing footprint of over 250,000 square meters built to international cGMP standards, Gentolex delivers complete end-to-end integration: from raw intermediate chemistry, custom solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and small molecule synthesis, to full Finished Dosage Form (FDF) licensing out and regulatory compliance support (DMF/CEP).
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable, and cost-effective chemical synthesis solutions across all clinical stages.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Full DMF/CEP documentation supported globally.
Targeted contract research, process chemistry optimization, peptide sequence modification (lipidation, PEGylation, cyclization), and custom analytical method validation (RP-HPLC, LC-MS, NMR).
For clients seeking to eliminate single-source risks, we provide streamlined procurement services leveraging top-tier supply network audits, raw material verification, and end-to-end logistics.
Out-licensing finished dosage formulations (inhalable solutions, dry powder formulations, injectable peptides) complete with dossiers ready for regional regulatory submissions.
Turnkey engineering consultation for biopharma startups and state facilities, providing reactor configuration, cleanroom validation (Class 100 to 100,000), and automated purification systems.
The clinical application of peptides and active pharmaceutical ingredients supplied by OEM respiratory exporters spans several acute and chronic therapeutic fields. Below are four key technical applications engineered by Gentolex's custom chemical and peptide synthesis units:
In severe pulmonary pathologies such as ARDS, alveolar epithelial cells suffer microvascular ischemia and mitochondrial damage. SS-31 (Elamipretide API) targets cardiolipin in the inner mitochondrial membrane, inhibiting cytochrome c release and restoring ATP production. OEM supply of high-purity Elamipretide facilitates clinical progress in inhalable aerosol formulations for pulmonary endothelial protection.
Vasoactive peptide analogues such as Terlipressin Acetate and Carbetocin exert selective agonist activity on vasopressin V1a receptors. Beyond esophageal variceal hemorrhage, these peptides serve as clinical benchmarks for managing systemic vascular collapse and hepatorenal syndrome associated with respiratory failure in intensive care units.
Peptides like Thymosin Beta-4 (Tβ4) API and BPC-157 API trigger actin sequestration and promote cell migration, microvascular angiogenesis, and anti-inflammatory cascade regulation. OEM production of these sequences enables advanced formulations designed to mitigate chronic fibrotic remodeling of pulmonary tissues post-viral infection.
Developing peptide APIs for inhalation requires tight particle size distribution (D50 < 5 µm), low hygroscopicity, and residual solvent control. Gentolex's custom processing ensures fine chemical intermediates match stringent physical specifications needed for dry powder inhalers (DPI) and soft-mist nebulizers.
The chemical synthesis of complex bio-peptides (e.g., Semaglutide, Pegcetacoplan, Glucagon, Tesamorelin) requires continuous technological evolution. As a forward-thinking OEM Exporter, Gentolex invests heavily in next-generation manufacturing platforms to increase atom economy, lower manufacturing costs, and ensure zero-defect regulatory compliance.
Combining automated Solid-Phase Peptide Synthesis for fragment assembly with Liquid-Phase condensation allows commercial scale-up of 30+ amino acid sequences (e.g., Glucagon, Semaglutide) at multi-kilogram batches without yield decay.
Real-time spectral monitoring (UV, Mass Spec, UPLC) during elution guarantees chromatographic purity exceeding 99.0%, keeping optical isomer impurities below strict ICH threshold limits.
Implementation of eco-friendly coupling reagents (DIC/Oxyma) and closed-loop solvent recovery units cuts carbon footprint and hazardous effluent volume by 65%, meeting modern ESG compliance requirements for global buyers.
The strategic advantage of sourcing from established Chinese pharmaceutical exporters lies in robust chemical infrastructure, upstream raw material self-sufficiency, and unparalleled manufacturing scale. Gentolex's manufacturing complex in China represents a benchmark in industrial efficiency:
Connecting the world with guaranteed biopharmaceutical products, advanced peptide technologies, and international standard supply solutions.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Audited manufacturing compliance aligned with international pharmacopeia standards (USP, EP, JP).
In-depth chemical reports, therapeutic mechanism reviews, and peptide synthesis updates from our senior R&D team.
Introduction to Selank Acetate API: Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient (API) composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of the endogenous tuftsin fragment engineered for metabolic stability and targeted receptor interaction.
View Details
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier: As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and commercial contract partners requiring high analytical batch consistency.
View Details
Introduction: BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory pathway regulation under strict research protocols.
View Details
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment, features unique physiological properties validated by modern analytics.
View Details
SS-31 (Elamipretide) API: SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. By stabilizing mitochondrial structure and supporting cellular bioenergetics, SS-31 has gained significant global scientific focus.
View DetailsDirect technical and commercial answers for pharmaceutical buyers, regulatory specialists, and contract R&D leaders.
A: Every commercial batch of peptide API or chemical intermediate is shipped with a comprehensive Certificate of Analysis (COA), High-Performance Liquid Chromatography (HPLC) profiles, Mass Spectrometry (MS) verification, Residual Solvent Testing (GC), Heavy Metals analysis, and Endotoxin quantification. Drug Master Files (DMF) and cGMP statements are available for regulatory licensing.
A: Our R&D team reviews sequence complexity, solubility requirements, and structural modifications (such as N-terminal acetylation, C-terminal amidation, disulfide bridge formation, or lipid conjugation). We perform pilot-scale synthesis (gram level) before optimizing process yield for multi-kilogram production lines inside our 250,000 m² footprint.
A: Gentolex provides full FDF out-licensing packages for select therapeutic categories. This includes CTD Dossier preparation (Modules 1-5), stability study data under ICH accelerated conditions, process validation data, and localized regulatory submission assistance for target import markets in LATAM, Africa, and Asia.
A: We operate validated cold-chain logistics. Lyophilized peptide powders are packed with temperature-monitored insulation systems (-20°C or 2-8°C refrigerated freight) supported by real-time GPS/temperature data loggers to ensure zero loss of bioactivity during cross-border transit.
A: Yes. Beyond direct product supply, our engineering division offers turn-key technical consultation for regional pharma companies seeking to set up local synthesis suites, HPLC purification columns, or cGMP-compliant cleanroom environments.
A: Sourcing through Gentolex integrates your pipeline into China's complete chemical ecosystem. This mitigates upstream raw material shortages, drastically lowers manufacturing overhead, and guarantees scalable production velocity for expanding clinical trial phases.
Explore our full line of fine chemicals, bioactive peptides, and structural intermediates engineered for worldwide dispatch.
